Heparan Sulfate Proteoglycans
Research News and Information

Sunday, November 22, 2009

The core protein of glypican Dally-like determines its biphasic activity in wingless morphogen signaling.

29 Sep 2009 Dally-like (Dlp) is a glypican-type heparan sulfate proteoglycan (HSPG), containing a protein core and attached glycosaminoglycan (GAG) chains. In Drosophila wing discs, Dlp represses short-range Wingless (Wg) signaling, but activates long-range Wg ... Read more...

Compositional analysis of heparin/heparan sulfate interacting with fibroblast growth factor.fibroblast growth factor receptor complexes.

6 Sep 2009 Heparan sulfate (HS) proteoglycans (PGs) interact with a number of extracellular signaling proteins, thereby playing an essential role in the regulation of many physiological processes. One major function of HS is to interact with fibroblast growth ... Read more...

Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development.

25 Aug 2009 RATIONALE: Tissue factor pathway inhibitor (TFPI) is a potent regulator of the tissue factor pathway and is found in plasma in association with lipoproteins. OBJECTIVE: To determine the role of TFPI in the development of atherosclerosis, we bred ... Read more...

Latest indexed articles for 'Heparan Sulfate Proteoglycans'

These are the very latest articles for this heading:

• The core protein of glypican Dally-like determines its biphasic activity in wingless morphogen signaling. 29 Sep 2009
• Compositional analysis of heparin/heparan sulfate interacting with fibroblast growth factor.fibroblast growth factor receptor complexes. 6 Sep 2009
• Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development. 25 Aug 2009
• HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium. 4 Aug 2009
• Biological activity of ectodysplasin A is conditioned by its collagen and heparan sulfate proteoglycan-binding domains. 3 Aug 2009
• Netrin-DCC, Robo-Slit, and heparan sulfate proteoglycans coordinate lateral positioning of longitudinal dopaminergic diencephalospinal axons. 13 Jul 2009
• Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion. 12 Jul 2009
• Force spectroscopy of the interaction between mycobacterial adhesins and heparan sulphate proteoglycan receptors. 11 Jul 2009
• Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. 29 Jun 2009
• Electrophysiological studies in a mouse model of Schwartz-Jampel syndrome demonstrate muscle fiber hyperactivity of peripheral nerve origin. 29 Jun 2009
• Tissue distribution of perlecan domains III and V during embryonic and fetal human development. 29 Jun 2009
• Cell type-specific requirements for heparan sulfate biosynthesis at the Drosophila neuromuscular junction: effects on synapse function, membrane trafficking, and mitochondrial localization. 29 Jun 2009
• Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association. 22 Jun 2009
• Human immunodeficiency virus downregulates podocyte apoE expression. 22 Jun 2009
• The modulation of platelet and endothelial cell adhesion to vascular graft materials by perlecan. 19 Jun 2009
• The signaling mechanisms of syndecan heparan sulfate proteoglycans. 13 Jun 2009
• Association analysis of genes involved in the maintenance of the integrity of the extracellular matrix with intracranial aneurysms in a Japanese cohort. 3 Jun 2009
• Down syndrome critical region protein 5 regulates membrane localization of Wnt receptors, Dishevelled stability and convergent extension in vertebrate embryos. 30 May 2009
• Long-term transduction of miniature pig parotid glands using serotype 2 adeno-associated viral vectors. 30 May 2009
• Heparan sulfate proteoglycans in extravasation: assisting leukocyte guidance. 30 May 2009

See a longer list of these articles.

Technical information about 'Heparan Sulfate Proteoglycans'

Definition: Ubiquitous macromolecules associated with the cell surface and extracellular matrix of a wide range of cells of vertebrate and invertebrate tissues. They are essential cofactors in cell-matrix adhesion processes, in cell-cell recognition systems, and in receptor-growth factor interactions. (From Cancer Metastasis Rev 1996; 15(2): 177-86; Hepatology 1996; 24(3): 524-32)

Registry Number: 0

Descriptor UI: D019812

Alternative terms: Heparan Sulfate Proteoglycans; Proteoglycans, Heparan Sulfate; Sulfate Proteoglycans, Heparan; HSPG; Proteoheparan Sulfate; Heparan Sulfate Proteoglycan; Proteoglycan, Heparan Sulfate;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D09.698.373.425.500; D09.698.735.400; D12.776.395.650.350;

History Note: 2006(1982)

Technical Notes: do not confuse with HEPARAN SULFATE see HEPARITIN SULFATE